

October 21, 2009

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
TOHO HOLDINGS CO., LTD.
(Tokyo Stock Exchange Securities Code: 8129)
Norio Hamada, President and CEO
Contact: Mamoru Ogino, Corporate Officer and
General Manager of Financial Department
(Tel: 03-4330-3735)

Notice of the Revision of the Earnings Forecasts for the Second Quarter of Fiscal 2010

TOHO HOLDINGS CO., LTD. hereby announces that, in the light of matters such as recent trends in the Company's performance, it has revised its cumulative consolidated earnings forecasts for the second quarter of the fiscal year ending March 2010, which were announced on May 8, 2009, as follows:

1. Revision of the cumulative consolidated forecast for the 2nd quarter of the fiscal year ending March 2010
(From April 1, 2009 to September 30, 2009)

(Unit: million yen, %)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share
Previous forecast (A)	million yen 463,000	million yen 1,800	million yen 3,300	million yen 1,700	yen 28.96
Revised forecast (B)	476,500	2,900	4,400	2,100	35.77
Increase/Decrease (B-A)	13,500	1,100	1,100	400	
Change (%)	2.9	61.1	33.3	23.5	
Result of fiscal 2009	409,429	4,370	6,110	-2,896	-45.68

2. Reason for the Revision

The cumulative consolidated sales for the 2nd quarter of the fiscal year ending March 2010 are estimated to exceed the initial projection by 13,500 million yen, assisted by the growth of sales thanks to appreciation by the customers of its original proposal-based marketing and sales activities based on the pillar of customer support systems and increasing demand for pharmaceuticals related to the outbreak of a new subtype of influenza. As for profits, both operating income and ordinary income will exceed the initial projections by 1,100 million yen respectively, since the Company has curbed SGA expenses while maintaining a policy of securing adequate profits. The consolidated net income will exceed the start of the term projection by 400 million yen. With regard to the full-term earnings forecasts, the Company has not changed the forecasts previously announced, since movements by pharmaceutical manufacturers regarding the invoice prices are not clear at this stage before the revision of the NHI Drug Price Standards comes into effect in April 2010.

(Note) The above earnings forecasts have been prepared based on information available as of the announcement date of this document. Actual performance may differ from forecasted figures for various reasons.